PHARMACOLOGY 1
🇬🇧
In English
In English
Practice Known Questions
Stay up to date with your due questions
Complete 5 questions to enable practice
Exams
Exam: Test your skills
Test your skills in exam mode
Learn New Questions
Popular in this course
Learn with flashcards
Manual Mode [BETA]
Select your own question and answer types
Other available modes
Complete the sentence
Listening & SpellingSpelling: Type what you hear
multiple choiceMultiple choice mode
SpeakingAnswer with voice
Speaking & ListeningPractice pronunciation
TypingTyping only mode
PHARMACOLOGY 1 - Leaderboard
PHARMACOLOGY 1 - Details
Levels:
Questions:
870 questions
🇬🇧 | 🇬🇧 |
The science of substances used to prevent, diagnose and treat disease. | Medical Pharmacology |
The science of drug preparation and the medical use of drugs -- the precursor of pharmacology | Materia Medica |
Two General Principles (PHARMACOLOGY) | 1 All substances can under circumstances be toxic, and the chemicals in botanicals are no different from chemicals in manufactured drugs except for the proportion of impurities 2 All dietary supplements and all therapies promoted as health-enhancing should meet the same standards of efficacy and safety as conventional drugs and medical therapies |
The study of the GENETIC VARIATIONS that cause differences in drug response among individuals or populations. | Pharmacogenomics (also called Pharmacogenetics) |
The use of drugs to prevent and treat disease | Pharmacotherapeutics |
Brand name/ Proprietary name Selected by the drug company selling the product Protected by copyright | Trade Name |
Family Drugs that share similar characteristics Ex: Beta-adrenergic blockers | Pharmacologic Class |
Groups drugs by therapeutic use Ex: Antihypertensives | Therapeutic Class |
POWER PLANT: | 1 Alkaloids 2 Glycosides 3 Gums 4 Resins 5 Oils |
Animal Magnetism Drugs obtained from animal sources | 1 hormones such as insulin 2 oils and fats (usually fixed) - cod liver oil 3 enzymes - pancreatin and pepsin 4 vaccines |
Mineral Springs: __ | • Iron • Iodine • Epsom salt |
Drugs produced in the laboratory | Down to DNA |
Routes of Administration | • buccal, sublingual, translingual • gastric • intradermal • intramuscular • intravenous • oral • rectal and vaginal • respiratory • subcutaneous • topical |
1 activator -has affinity to the receptor and intrinsic activity 2 Inhibitor -has affinity only | 1 AGONIST 2 ANTAGONIST |
Inhibitor has affinity only | ANTAGONIST |
May interact directly with other drugs | Chemical Antagonists |
The Physical Nature of Drugs | • Solid - Aspirin, Atropine • Liquid - Nicotine, Ethanol • Gaseous - Nitrous Oxide |
Drug Size, SMALLEST and LARGEST | 1 Smallest -- Lithium ion (MW 7) 2 Largest -- Alteplase (MW 59,050) 3 Most drugs -- MW 100-1000 |
Three major types of bonds | 1 covalent, 2 electrostatic and 3 hydrophobic |
Implies the ability to predict the appropriate molecular structure of a drug on the basis of information about its biologic receptor | Rational Drug Design |
Must undergo extensive animal studies | IND - Investigational New Drug |
1 actions of drug on the body 2 actions of the body on the drug | 1 Pharmacodynamics 2 Pharmacokinetics |
Involves trials with people who have the disease for which the drug is thought to be effective. | Phase II |
Exceptions to the Rule | 1 Public health threat of disease like AIDS, COVID-19 2 Sponsors of drugs that reach phase II or III clinical trials can apply for FDA approval of treatment IND status |
1 actions of drug on the body 2 actions of the body on the drug | 1 Pharmacodynamics 2 Pharmacokinetics |
LADMERS | • Liberation of an active ingredient from the dosage form • Absorption into systemic circulation • Distribution • Metabolism in the body • Excretion of the drug from the body • Response |
• directly proportional to the concentrations, surface area and permeability coefficient • inversely proportional to the thickness of the membrane | Fick's Law of Diffusion |
Reverse of endocytosis | Exocytosis |
Factors influencing absorption | 1 Effect of pH on drug absorption 2 Blood flow to the absorption site 3 Total surface area available for absorption 4 Contact time at the absorption surface |
Absorbs nutrients in the small intestine | Microvilli |
Responsible for transporting various molecules, including drugs, across cell membranes - "pumps" drugs out of the cells - associated with multi-drug resistance | Expression of P-glycoprotein |
Bioavailability is usually measured using __ | Area Under the Curve (AUC) |
1) 100% Bioavailability, most rapid onset 2) 5 to <100 Bioavailability, most convenient; may have significant First Pass Effect | 1 Intravenous 2 Oral |
Factors Influencing Bioavailability: when a drug is absorbed from the GI tract, it enters the PORTAL CIRCULATION before entering the systemic circulation | First-pass Hepatic Metabolism |
Factors Influencing Bioavailability | 1 First-pass Hepatic Metabolism 2 Solubility of the drug 3 Chemical instability 4 Nature of the drug formulation |
Show comparable bioavailability and similar times to achieve peak blood concentrations | BIOEQUIVALENCE |
Pharmaceutically equivalent with similar chemical and safety profiles | THERAPEUTIC EQUIVALENCE |
If the drugs have the same dosage form, contain the same active ingredient, and use the same route of administration | Pharmaceutical Equivalence |
The process by which a drug reversibly leaves the bloodstream and enters the instertitium (extracellular fluid) and the tissues | DRUG DISTRIBUTION |
The process by which a drug reversibly leaves the bloodstream and enters the instertitium (extracellular fluid) and the tissues. | DRUG DISTRIBUTION |
What are the Special Barriers to Distribution? | 1 Placental (most small molecular weight drugs cross the placental barrier; fetal blood levels are usually lower than maternal) 2 Blood-brain (permeable only to lipid-soluble drugs or those of very low molecular weight) |
• Concentration of drug at the receptor site • Commonly measured in the blood (Exception for topical agents) | EFFECTIVE DRUG CONCENTRATION |
Plasma concentration is a function of | – the rate of input of the drug (by absorption) into the plasma – the rate of distribution – and the rate of elimination |
Pharmacokinetics TWO BASIC PARAMETERS | 1 CLEARANCE 2 VOLUME OF DISTRIBUTION |
The measure of the apparent space in the body available to contain the drug. | VOLUME OF DISTRIBUTION |
The ratio of the amount of drug in the body to the drug concentration in the plasma or blood | Volume of distribution -Can be affected by liver and kidney disease |
METABOLISM OF DRUGS Three major routes: | – Hepatic metabolism – Biliary metabolism – Urinary metabolism |
Metabolism (Biotransformation) PHASES | 1) Phase I (Functionalization) – Redox Reactions and hydrolysis. 2) Phase II (Conjugation) – Attacks certain drugs with existing functional groups and attaches conjugate molecules |
Metabolism (Biotransformation) May be affected by | • Drug Interactions due to inducers, inhibitors, and substrates • Genetic factors • Disease states DRUG WITH INDUCER - FASTER DRUGS WITH INHIBITOR - SLOWER |
EXCRETION; Renal elimination of drugs: | – Glomerular filtration – Proximal tubular secretion – Distal tubular reabsorption |
Excretion process | 1 Glomerular filtration of water and unbound drugs and metabolites 2 Active tubular secretion of acidic and basic drugs and metabolites 3 Active reabsorption of acidic and basic endogenous compounds and passive reabsorption of lipophilic drugs 4 Urinary excretion of drugs and metabolites that are filtered and or actively secreted and not reabsorbed |
Describes the actions of a drug on the body and the influence of drug concentrations on the magnitude of the response | PHARMACODYNAMICS |
• Their ligands are presently unknown • May prove useful targets for the development of new drugs. | ORPHAN RECEPTORS |
• MEDIATE the actions of endogenous chemical signals such as neurotransmitters, autacoids and hormones. | REGULATORY PROTEINS |
Membrane receptor for digitalis glycosides a TRANSPORT PROTEIN | Na+/K+ ATPase Pump |
Ionotropic receptors associated with ligand-gated ion channels Features: LOCATION = __ EFFECT = __ | CLASS 1 LOCATION: Cell membrane EFFECT: millisecond |
Controls Na+ channels (Ligand-gated) -- inhibited by curare and derivatives, ganglionic blockers | Nicotinic Receptor (CLASS 1) |
Controls Cl- channels | GABAA-receptor complex (CLASS 1) |
Metabotropic 7 transmembrane-spanning G-protein-linked Features: LOCATION = __ EFFECT= __ | Class II LOCATION: Cell membrane EFFECT: Seconds |
G-proteins: __ | 1) Gs 2) Gi 3) Gq |
Activates adenylyl cyclase which produces the second messenger cyclic adenosine monophosphate (cAMP) | Gs |
Enzyme-linked receptors • Features: EFFECT = __; possesses tyrosine kinase activity as part of their structure | Class III EFFECT: minutes to hours |
CLASS III example | • Epidermal growth factor • Atrial natriuretic peptide • Insulin |